Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus

AIMS/INTRODUCTION: Dapagliflozin is used for individuals with type 1 diabetes, although the effect of this medication on skeletal muscle mass is not well established. In addition, there are few studies examining the effects of good glycemic control on skeletal muscle mass in type 1 diabetes patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Yuta, Hashimoto, Yoshitaka, Okada, Hiroshi, Takegami, Maya, Nakajima, Hanako, Miyoshi, Tomoki, Yoshimura, Takashi, Yamazaki, Masahiro, Hamaguchi, Masahide, Fukui, Michiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512910/
https://www.ncbi.nlm.nih.gov/pubmed/37424302
http://dx.doi.org/10.1111/jdi.14054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512910/
https://www.ncbi.nlm.nih.gov/pubmed/37424302
http://dx.doi.org/10.1111/jdi.14054

Ejemplares similares